Proteros generates structurally enabled, qualified hit and lead series to unlock challenging targets, de-risk early discovery programs, and accelerate the initiation of drug discovery projects. As a protein- and structure-centric company with deep expertise in protein science, structural biology, assays, biophysics, and screening, Proteros is uniquely positioned to execute successful hit identification (HitID) and hit-to-lead (H2L) campaigns. These capabilities are further strengthened by a differentiated portfolio of fragment and lead-like libraries and an extensive range of complementary screening technologies, including crystallography, SPR, ¹⁹F-NMR, mass spectrometry, enzymatic assays, reporter displacement assays, and complex formation assays.

Proteros has broad experience across diverse mechanisms of action, including inhibitors, activators, correctors, PPI blockers, destabilizers, molecular glues, RIPTACs, PROTACs, and allosteric, orthosteric, and covalent binders. Its expertise spans a wide range of target classes, including enzymes, RNA- and DNA-binding proteins, scaffolding proteins, transcription factors, and receptors. Particularly high success rates can be achieved through Proteros’ sophisticated crystallographic fragment screening (CFS) platform, which combines high-throughput structural screening with structure-based, one-step fragment expansion toward lead-like compounds. In parallel, Proteros operates one of the largest SPR facilities in the world, enabling library screening at HTS scale. Combined with proprietary data analysis workflows, this capability allows the identification of unique and actionable binders, including chemical matter that may be challenging to discover using conventional approaches.

Through this integrated combination of protein science, structural biology, biophysics, screening, and medicinal chemistry-enabling capabilities, Proteros identifies structurally enabled and trackable chemical matter that provides a strong foundation for advancing challenging targets and kick-starting early drug discovery programs.